Primary results from the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE)

Journal of the Neurological Sciences

Volumn 349, Issue 1-2, 2015, Pages 84-93

  Jankovic, Joseph ^a   Adler, Charles H ^b   Charles, David ^c   Comella, Cynthia ^d   Stacy, Mark ^e   Schwartz, Marc ^f   Manack Adams, Aubrey ^g   Brin, Mitchell F ^g,h  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f MedNet Solutions   (United States)

^g ALLERGAN INC   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Botulinum toxin; Cervical dystonia; OnabotulinumtoxinA; Pain; Torticollis

Indexed keywords

BOTULINUM TOXIN A; ACETYLCHOLINE RELEASE INHIBITOR;

ADULT; ARTICLE; CERVICAL DYSTONIA; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; ELECTROMYOGRAPHY; FEMALE; HUMAN; INCIDENCE; LOW DRUG DOSE; MALE; MEDICAL SPECIALIST; MULTICENTER STUDY (TOPIC); MUSCLE WEAKNESS; NECK PAIN; NEUROLOGIST; OUTCOME ASSESSMENT; PHYSICAL MEDICINE; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; TORTICOLLIS; TREATMENT DURATION; TREATMENT OUTCOME; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; REGISTER;

ACETYLCHOLINE RELEASE INHIBITORS; ADULT; AGED; BOTULINUM TOXINS, TYPE A; DEGLUTITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE WEAKNESS; OBSERVATIONAL STUDY AS TOPIC; PROSPECTIVE STUDIES; REGISTRIES; TORTICOLLIS; TREATMENT OUTCOME;

EID: 84924007555     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2014.12.030     Document Type: Article

References (29)

1. A. Albanese, K. Bhatia, S.B. Bressman, M.R. Delong, S. Fahn, and V.S. Fung Phenomenology and classification of dystonia: a consensus update Mov Disord 28 7 2013 863 873
2. G. Defazio, J. Jankovic, J.L. Giel, and S. Papapetropoulos Descriptive epidemiology of cervical dystonia Tremor Other Hyperkinet Mov (N Y) 3 2013 1 8
3. L. Camfield, Y. Ben-Shlomo, and T.T. Warner Impact of cervical dystonia on quality of life Mov Disord 17 4 2002 838 841
4. J. Slawek, A. Friedman, A. Potulska, P. Krystkowiak, C. Gervais, and M. Banach Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections Funct Neurol 22 2 2007 95 100
5. J. Müller, G. Kemmler, J. Wissel, A. Schneider, B. Voller, and J. Grossmann The impact of blepharospasm and cervical dystonia on health-related quality of life and depression J Neurol 249 7 2002 842 846
6. M. Hallett, A. Albanese, D. Dressler, K.R. Segal, D.M. Simpson, and D. Truong Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders Toxicon 67 2013 94 114
7. J. Ramirez-Castaneda, and J. Jankovic Long-term efficacy and safety of botulinum toxin injections in dystonia Toxins (Basel) 5 2 2013 249 266
8. D. Charles, A. Brashear, R.A. Hauser, H.I. Li, L.M. Boo, and M.F. Brin Efficacy, tolerability, and immunogenicity of onabotulinumtoxinA in a randomized, double-blind, placebo-controlled trial for cervical dystonia Clin Neuropharmacol 35 5 2012 208 214
9. M.F. Brin, C.L. Comella, J. Jankovic, F. Lai, and M. Naumann Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay Mov Disord 23 10 2008 1353 1360
10. W.R. Galpern, C.S. Coffey, A. Albanese, K. Cheung, C.L. Comella, and D.J. Ecklund Designing clinical trials for dystonia Neurotherapeutics 11 1 2014 117 127
11. A. Manack, C.C. Turkel, and H. Kaplowitz Role of epidemiological data within the drug development lifecycle: a chronic migraine case study N. Lunet, Epidemiology - Current Perspectives on Research and Practice 2012 InTech
12. J. Jankovic, C.H. Adler, P.D. Charles, C. Comella, M. Stacy, and M. Schwartz Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE) BMC Neurol 11 2011 140
13. C.L. Comella, G.T. Stebbins, C.G. Goetz, T.A. Chmura, S.B. Bressman, and A.E. Lang Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale Mov Disord 12 4 1997 570 575
14. A. Albanese, F.D. Sorbo, C. Comella, H.A. Jinnah, J.W. Mink, and B. Post Dystonia rating scales: critique and recommendations Mov Disord 28 7 2013 874 883
15. E. Consky, and A. Lang Clinical assessments of patients with cervical dystonia J. Jankovic, M. Hallett, Therapy with botulinum toxin 1994 Marcel Dekker, Inc. New York, NY 211 237
16. W. Guy, and R.R. Bonato Manual for the ECDEU assessment battery 2nd revised ed. 1976 National Institute of Mental Health Chevy Chase
17. D. Fischer, A.L. Stewart, D.A. Bloch, K. Lorig, D. Laurent, and H. Holman Capturing the patient's view of change as a clinical outcome measure JAMA 282 12 1999 1157 1162
18. S.J. Cano, T.T. Warner, J.M. Linacre, K.P. Bhatia, A.J. Thompson, and R. Fitzpatrick Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58) Neurology 63 9 2004 1629 1633
19. S.J. Cano, J.C. Hobart, M. Edwards, R. Fitzpatrick, K. Bhatia, and A.J. Thompson CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia Neurology 67 12 2006 2230 2232
20. E.G. Brown, L. Wood, and S. Wood The medical dictionary for regulatory activities (MedDRA) Drug Saf 20 2 1999 109 117
21. C.L. Comella, J. Jankovic, D.D. Truong, A. Hanschmann, and S. Grafe Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia J Neurol Sci 308 1-2 2011 103 109
22. D. Truong, M. Brodsky, M. Lew, A. Brashear, J. Jankovic, and E. Molho Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia Parkinsonism Relat Disord 16 5 2010 316 323
23. M.F. Brin, M.F. Lew, C.H. Adler, C.L. Comella, S.A. Factor, and J. Jankovic Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia Neurology 53 7 1999 1431 1438
24. A. Brashear, M.F. Lew, D.D. Dykstra, C.L. Comella, S.A. Factor, and R.L. Rodnitzky Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia Neurology 53 7 1999 1439 1446
25. D. Truong, D.D. Duane, J. Jankovic, C. Singer, L.C. Seeberger, and C.L. Comella Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study Mov Disord 20 7 2005 783 791
26. BOTOX® summary of product characteristics 2013 Allergan Ltd. Marlow, UK
27. N.I. Mejia, K.D. Vuong, and J. Jankovic Long-term botulinum toxin efficacy, safety, and immunogenicity Mov Disord 20 5 2005 592 597
28. P.S. Belperio, E.W. Hwang, I.C. Thomas, L.A. Mole, R.C. Cheung, and L.I. Backus Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C Clin Gastroenterol Hepatol 11 8 2013 1021 1027
29. M.S. Heiberg, W. Koldingsnes, K. Mikkelsen, E. Rødevand, C. Kaufmann, and P. Mowinckel The comparative one-year performance of anti-tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study Arthritis Rheum 59 2 2008 234 240